Based on more than two decades of expertise in the field of gene- and immunotherapy, GeneWerk GmbH was founded 2014 in the heart of biotechnology metropolitan area Rhein-Neckar, Germany. Our business partners appreciate our worldwide unique experience in assessing vector safety and efficacy in gene therapy and immune repertoire studies as well as partner for research projects based on Next Generation Sequencing. We provide highly sensitive molecular services and standardized as well as customized bioinformatics analyses. Applications include clonality and safety assessment of gene-modified cells by using integrating and non-integrating viral vectors in gene therapy; On/off-target specificity of designer nucleases (TALEN, ZFN, CRISPR-Cas9 and Meganucleases) and immune repertoire studies in T and B cells. Operating within several research consortia, such as EU horizon 2020 SCIDNet, RECOMB, and GSK/Novartis founded CRACK-it challenges, allows us to focus on our mission - to improve the safety of novel gene and immune-gene therapies for patients and help reducing the reliance on animal models.